Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease

نویسندگان

  • Stephen Salloway
  • Jose E. Gamez
  • Upinder Singh
  • Carl H. Sadowsky
  • Teresa Villena
  • Marwan N. Sabbagh
  • Thomas G. Beach
  • Ranjan Duara
  • Adam S. Fleisher
  • Kirk A. Frey
  • Zuzana Walker
  • Arvinder Hunjan
  • Yavir M. Escovar
  • Marc E. Agronin
  • Joel Ross
  • Andrea Bozoki
  • Mary Akinola
  • Jiong Shi
  • Rik Vandenberghe
  • Milos D. Ikonomovic
  • Paul F. Sherwin
  • Gill Farrar
  • Adrian P.L. Smith
  • Christopher J. Buckley
  • Dietmar Rudolf Thal
  • Michelle Zanette
  • Craig Curtis
چکیده

INTRODUCTION Performance of the amyloid tracer [18F]flutemetamol was evaluated against three pathology standard of truth (SoT) measures including neuritic plaques (CERAD "original" and "modified" and the amyloid component of the 2012 NIA-AA guidelines). METHODS After [18F]flutemetamol imaging, 106 end-of-life patients who died underwent postmortem brain examination for amyloid plaque load. Blinded positron emission tomography scan interpretations by five independent electronically trained readers were compared with pathology measures. RESULTS By SoT, sensitivity and specificity of majority image interpretations were, respectively, 91.9% and 87.5% with "original CERAD," 90.8% and 90.0% with "modified CERAD," and 85.7% and 100% with the 2012 NIA-AA criteria. DISCUSSION The high accuracy of either CERAD criteria suggests that [18F]flutemetamol predominantly reflects neuritic amyloid plaque density. However, the use of CERAD criteria as the SoT can result in some false-positive results because of the presence of diffuse plaques, which are accounted for when the positron emission tomography read is compared with the 2012 NIA-AA criteria.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection

In vivo imaging of fibrillar β-amyloid deposits may assist clinical diagnosis of Alzheimer's disease (AD), aid treatment selection for patients, assist clinical trials of therapeutic drugs through subject selection, and be used as an outcome measure. A recent phase III trial of [18F]flutemetamol positron emission tomography (PET) imaging in 106 end-of-life subjects demonstrated the ability to i...

متن کامل

[18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β pathology

BACKGROUND Amyloid positron emission tomography (PET) has become an important tool to identify amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. Here, we determined the diagnostic value of the amyloid PET tracer [(18)F]flutemetamol in relation to Aβ pathology at autopsy. METHODS [(18)F]flutemetamol PET was carried out in a cohort of 68 patients included in a [(18)F]flutemetamol a...

متن کامل

The diagnostic difference between 18F- FDG PET and 99mTc-HMPAO SPECT perfusion imaging in assessment of Alzheimer's disease

Introduction:Brain imaging with F-18 fluorodeoxyglucose (18F-FDG) positron ‎emission tomography or Tc-99m hexamethylpropyleneamine oxime (‎99mTc-HMPAO) SPECT is widely used for the evaluation of Alzheimer's ‎dementia (AD); we aim to assess superiority of one method over the ‎other. Methods: Twenty four patients with clinical diagnosi...

متن کامل

Clinical Neuropathology Practice News 3-2012: the “ABC” in AD – revised and updated guideline for the neuropathologic assessment of Alzheimer’s disease

The two major approaches for the neuropathological assessment of Alzheimer's disease (AD) related pathology have been based on the assessment of neuritic plaques (CERAD) and neurofibrillary pathology (Braak and Braak). In 1997 these two approaches were integrated in the criteria and recommendations of the National Institute on Aging and the Reagan Institute Working group. Recently a new guideli...

متن کامل

Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease.

The National Institute on Aging and Reagan Institute (NIA-RI) criteria, and other neuropathologic criteria for Alzheimer's disease (AD), were compared with the clinical diagnosis of dementia in a well defined population of Catholic sisters. The 47-participant subset examined in this study were college educated and lacked complicating conditions such as brain infarcts or diffuse Lewy body diseas...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 9  شماره 

صفحات  -

تاریخ انتشار 2017